Longitudinal exploration of cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma: protocol for a feasibility study
Introduction Cancer-related cognitive impairment (CRCI) is a distressing and disabling side-effect of cancer treatments affecting up to 75% of patients. For some patients, their cognitive impairment may be transient, but for a subgroup, these symptoms can be long-standing and have a major impact on...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-09-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/10/9/e038312.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841554951032012800 |
|---|---|
| author | Vincent Dore Christopher C Rowe Meinir Krishnasamy Haryana Dhillon Adam K Walker Karla Gough Priscilla Gates Carlene Wilson Eliza Hawkes Yuliya Perchyonok Janette L Vardy Michiel de Ruiter |
| author_facet | Vincent Dore Christopher C Rowe Meinir Krishnasamy Haryana Dhillon Adam K Walker Karla Gough Priscilla Gates Carlene Wilson Eliza Hawkes Yuliya Perchyonok Janette L Vardy Michiel de Ruiter |
| author_sort | Vincent Dore |
| collection | DOAJ |
| description | Introduction Cancer-related cognitive impairment (CRCI) is a distressing and disabling side-effect of cancer treatments affecting up to 75% of patients. For some patients, their cognitive impairment may be transient, but for a subgroup, these symptoms can be long-standing and have a major impact on the quality of life. This paper describes the protocol for a study: (1) to assess the feasibility of collecting longitudinal data on cognition via self-report, neuropsychological testing, peripheral markers of inflammation and neuroimaging and (2) to explore and describe patterns of cancer-related cognitive impairment over the course of treatment and recovery in patients with newly diagnosed, aggressive lymphoma undergoing standard therapy with curative intent.Methods and analysis This is a prospective, longitudinal, feasibility study in which 30 newly diagnosed, treatment-naive patients with aggressive lymphoma will be recruited over a 12-month period. Patients will complete comprehensive assessments at three time points: baseline (time 1, pre-treatment) and two post-baseline follow-up assessments (time 2, mid-treatment and time 3, 6–8 weeks post-treatment completion). All patients will be assessed for self-reported cognitive difficulties and objective cognitive function using Stroop Colour and Word, Trail Making Test Part A and B, Hopkins Verbal Learning Test-Revised, Controlled Oral Word Association and Digit Span. Blood cell-based inflammatory markers and neuroimaging including a positron emission tomography (PET) with 18F-labelled fluoro-2-deoxyglucose (18F-FDG) and CT (18F-FDG-PET/CT) and a MRI will explore potential inflammatory and neuroanatomical or functional mechanisms and biomarkers related to CRCI. The primary intent of analysis will be to assess the feasibility of collecting longitudinal data on cognition using subjective reports and objective tasks from patients during treatment and recovery for lymphoma. These data will inform the design of a larger-scale investigation into the patterns of cognitive change over the course of treatment and recovery, adding to an underexplored area of cancer survivorship research.Ethics and dissemination Ethical approval has been granted by Austin Health Human Rights Ethics Committee (HREC) in Victoria Australia. Peer reviewed publications and conference presentations will report the findings of this novel study.Trial registration number Australian New Zealand Clinical Trials Registry (ACTRN12619001649101). |
| format | Article |
| id | doaj-art-9204f7ea10f04c2ead956f206b0ddefe |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2020-09-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-9204f7ea10f04c2ead956f206b0ddefe2025-01-08T07:30:10ZengBMJ Publishing GroupBMJ Open2044-60552020-09-0110910.1136/bmjopen-2020-038312Longitudinal exploration of cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma: protocol for a feasibility studyVincent Dore0Christopher C Rowe1Meinir Krishnasamy2Haryana Dhillon3Adam K Walker4Karla Gough5Priscilla Gates6Carlene Wilson7Eliza Hawkes8Yuliya Perchyonok9Janette L Vardy10Michiel de Ruiter118 Biomedical Imaging, Health & Biosecurity Flagship, The Australian e-Health Research Centre, CSIRO Health & Biosecurity, Melbourne, Victoria, Australia1Florey Institute of Neurosciences and Mental Health, Parkville, VIC, Australia17 Academic Nursing Unit, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia5 Faculty of Science, School of Psychology, The University of Sydney, Sydney, New South Wales, Australia1 Macquarie University Centre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia3 Department of Cancer Experiences, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia1 Cognitive Neuroscience Unit, Deakin University, Burwood, Victoria, Australia5 Psycho-Oncology Research Unit, Austin Health, Heidelberg, Victoria, Australia1 Department of Clinical Haematology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Melbourne, Victoria, Australia7 Faculty of Medicine, Dentistry & Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia6 Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia15 Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The NetherlandsIntroduction Cancer-related cognitive impairment (CRCI) is a distressing and disabling side-effect of cancer treatments affecting up to 75% of patients. For some patients, their cognitive impairment may be transient, but for a subgroup, these symptoms can be long-standing and have a major impact on the quality of life. This paper describes the protocol for a study: (1) to assess the feasibility of collecting longitudinal data on cognition via self-report, neuropsychological testing, peripheral markers of inflammation and neuroimaging and (2) to explore and describe patterns of cancer-related cognitive impairment over the course of treatment and recovery in patients with newly diagnosed, aggressive lymphoma undergoing standard therapy with curative intent.Methods and analysis This is a prospective, longitudinal, feasibility study in which 30 newly diagnosed, treatment-naive patients with aggressive lymphoma will be recruited over a 12-month period. Patients will complete comprehensive assessments at three time points: baseline (time 1, pre-treatment) and two post-baseline follow-up assessments (time 2, mid-treatment and time 3, 6–8 weeks post-treatment completion). All patients will be assessed for self-reported cognitive difficulties and objective cognitive function using Stroop Colour and Word, Trail Making Test Part A and B, Hopkins Verbal Learning Test-Revised, Controlled Oral Word Association and Digit Span. Blood cell-based inflammatory markers and neuroimaging including a positron emission tomography (PET) with 18F-labelled fluoro-2-deoxyglucose (18F-FDG) and CT (18F-FDG-PET/CT) and a MRI will explore potential inflammatory and neuroanatomical or functional mechanisms and biomarkers related to CRCI. The primary intent of analysis will be to assess the feasibility of collecting longitudinal data on cognition using subjective reports and objective tasks from patients during treatment and recovery for lymphoma. These data will inform the design of a larger-scale investigation into the patterns of cognitive change over the course of treatment and recovery, adding to an underexplored area of cancer survivorship research.Ethics and dissemination Ethical approval has been granted by Austin Health Human Rights Ethics Committee (HREC) in Victoria Australia. Peer reviewed publications and conference presentations will report the findings of this novel study.Trial registration number Australian New Zealand Clinical Trials Registry (ACTRN12619001649101).https://bmjopen.bmj.com/content/10/9/e038312.full |
| spellingShingle | Vincent Dore Christopher C Rowe Meinir Krishnasamy Haryana Dhillon Adam K Walker Karla Gough Priscilla Gates Carlene Wilson Eliza Hawkes Yuliya Perchyonok Janette L Vardy Michiel de Ruiter Longitudinal exploration of cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma: protocol for a feasibility study BMJ Open |
| title | Longitudinal exploration of cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma: protocol for a feasibility study |
| title_full | Longitudinal exploration of cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma: protocol for a feasibility study |
| title_fullStr | Longitudinal exploration of cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma: protocol for a feasibility study |
| title_full_unstemmed | Longitudinal exploration of cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma: protocol for a feasibility study |
| title_short | Longitudinal exploration of cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma: protocol for a feasibility study |
| title_sort | longitudinal exploration of cancer related cognitive impairment in patients with newly diagnosed aggressive lymphoma protocol for a feasibility study |
| url | https://bmjopen.bmj.com/content/10/9/e038312.full |
| work_keys_str_mv | AT vincentdore longitudinalexplorationofcancerrelatedcognitiveimpairmentinpatientswithnewlydiagnosedaggressivelymphomaprotocolforafeasibilitystudy AT christophercrowe longitudinalexplorationofcancerrelatedcognitiveimpairmentinpatientswithnewlydiagnosedaggressivelymphomaprotocolforafeasibilitystudy AT meinirkrishnasamy longitudinalexplorationofcancerrelatedcognitiveimpairmentinpatientswithnewlydiagnosedaggressivelymphomaprotocolforafeasibilitystudy AT haryanadhillon longitudinalexplorationofcancerrelatedcognitiveimpairmentinpatientswithnewlydiagnosedaggressivelymphomaprotocolforafeasibilitystudy AT adamkwalker longitudinalexplorationofcancerrelatedcognitiveimpairmentinpatientswithnewlydiagnosedaggressivelymphomaprotocolforafeasibilitystudy AT karlagough longitudinalexplorationofcancerrelatedcognitiveimpairmentinpatientswithnewlydiagnosedaggressivelymphomaprotocolforafeasibilitystudy AT priscillagates longitudinalexplorationofcancerrelatedcognitiveimpairmentinpatientswithnewlydiagnosedaggressivelymphomaprotocolforafeasibilitystudy AT carlenewilson longitudinalexplorationofcancerrelatedcognitiveimpairmentinpatientswithnewlydiagnosedaggressivelymphomaprotocolforafeasibilitystudy AT elizahawkes longitudinalexplorationofcancerrelatedcognitiveimpairmentinpatientswithnewlydiagnosedaggressivelymphomaprotocolforafeasibilitystudy AT yuliyaperchyonok longitudinalexplorationofcancerrelatedcognitiveimpairmentinpatientswithnewlydiagnosedaggressivelymphomaprotocolforafeasibilitystudy AT janettelvardy longitudinalexplorationofcancerrelatedcognitiveimpairmentinpatientswithnewlydiagnosedaggressivelymphomaprotocolforafeasibilitystudy AT michielderuiter longitudinalexplorationofcancerrelatedcognitiveimpairmentinpatientswithnewlydiagnosedaggressivelymphomaprotocolforafeasibilitystudy |